| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.44 | 0.01 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.02 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.098 | 0.02 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.093 | 0.02 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.02 |